Aitor Abuin Blanco
Overview
Explore the profile of Aitor Abuin Blanco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beauverd Y, Ianotto J, Thaw K, Sobas M, Sadjadian P, Curto-Garcia N, et al.
Leukemia
. 2025 Mar;
PMID: 40074852
Essential thrombocythemia (ET) and polycythemia vera (PV) are rare in adolescent and young adult (AYA). These conditions, similar to those in older patients, are linked with thrombotic complications and the...
2.
Mosquera Orgueira A, Peleteiro Raindo A, Cid Lopez M, Antelo Rodriguez B, Diaz Arias J, Ferreiro Ferro R, et al.
PLoS One
. 2022 Sep;
17(9):e0274984.
PMID: 36107965
[This corrects the article DOI: 10.1371/journal.pone.0247093.].
3.
Sobas M, Kiladjian J, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih L, et al.
Blood Adv
. 2022 Jul;
6(17):5171-5183.
PMID: 35802458
Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers in 15 countries. Sequential patients...
4.
Mosquera Orgueira A, Cid Lopez M, Peleteiro Raindo A, Abuin Blanco A, Diaz Arias J, Gonzalez Perez M, et al.
Front Oncol
. 2022 Jan;
11:705010.
PMID: 35083135
Follicular Lymphoma (FL) has a 10-year mortality rate of 20%, and this is mostly related to lymphoma progression and transformation to higher grades. In the era of personalized medicine it...
5.
Mosquera Orgueira A, Gonzalez Perez M, Diaz Arias J, Antelo Rodriguez B, Alonso Vence N, Bendana Lopez A, et al.
Leukemia
. 2021 May;
35(10):2924-2935.
PMID: 34007046
Multiple myeloma (MM) remains mostly an incurable disease with a heterogeneous clinical evolution. Despite the availability of several prognostic scores, substantial room for improvement still exists. Promising results have been...
6.
Mosquera Orgueira A, Ferreiro Ferro R, Diaz Arias J, Aliste Santos C, Antelo Rodriguez B, Bao Perez L, et al.
PLoS One
. 2021 May;
16(5):e0248886.
PMID: 33945543
B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the...
7.
Mosquera Orgueira A, Peleteiro Raindo A, Cid Lopez M, Diaz Arias J, Gonzalez Perez M, Antelo Rodriguez B, et al.
Front Oncol
. 2021 Apr;
11:657191.
PMID: 33854980
Acute Myeloid Leukemia (AML) is a heterogeneous neoplasm characterized by cytogenetic and molecular alterations that drive patient prognosis. Currently established risk stratification guidelines show a moderate predictive accuracy, and newer...
8.
Mosquera Orgueira A, Cid Lopez M, Peleteiro Raindo A, Diaz Arias J, Antelo Rodriguez B, Bao Perez L, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33809641
There is growing evidence indicating the implication of germline variation in cancer predisposition and prognostication. Here, we describe an analysis of likely disruptive rare variants across the genomes of 726...
9.
Mosquera Orgueira A, Peleteiro Raindo A, Cid Lopez M, Antelo Rodriguez B, Diaz Arias J, Ferreiro Ferro R, et al.
PLoS One
. 2021 Feb;
16(2):e0247093.
PMID: 33592069
Background: FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both...
10.
Encinas M, Sobas M, Gomez-Casares M, Abuin Blanco A, Pereira M, Raya J, et al.
Eur J Haematol
. 2020 Dec;
106(3):371-379.
PMID: 33275803
Objectives: In patients with essential thrombocythemia (ET), after the JAK2V617F driver mutation, mutations in CALR are common (classified as type 1, 52-bp deletion or type 2, 5-bp insertion). CALR mutations...